Business Context and Reporting Period
This Form 8-K Current Report was filed by CalciMedica, Inc. on July 2, 2026. The filing addresses corporate governance changes, specifically the appointment of a new director and the announced retirement of an existing director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- New Appointment: Evgeny Zaytsev, M.D., Ph.D., was appointed as a Class I director effective immediately, with a term expiring at the 2027 annual meeting.
- Director Retirement: Fred Middleton announced his intention to retire from the Board effective at the 2026 annual meeting of stockholders. Upon his retirement, the Board size will decrease back to seven directors.
- Compensation Arrangements: Dr. Zaytsev will receive an annual cash retainer of $40,000 (pro-rated) and an option to purchase 20,000 shares of common stock, vesting monthly over three years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It explicitly states that Mr. Middleton's retirement is not the result of any disagreement with the Company regarding operations, policies, or practices. No unusual items or contingencies were disclosed.
Investor Verification Checklist
- Verify the professional background and qualifications of the new director, Dr. Evgeny Zaytsev.
- Confirm the exact date of the 2026 annual meeting to determine when the Board size will revert to seven members.
- Review the Company's standard Indemnity Agreement for directors referenced in the filing.
- Monitor future filings for any changes to the Board composition or executive leadership following these transitions.